

Convalescent Plasma for Critically-ill COVID-19 Patients

Adel A Aljatham^{1*}, Waleed T Hashim¹, Mohamad A Almashiakhi¹, Abdulrahman M Alharthy¹, Faisal A Alaklobi¹, Mohammed Adam¹, Assem A Elghazaly¹, Ahmed F Mady¹, Daood S Asad¹, Hala Aamr¹, Alaa H Alali¹, Juhaina Abdalraheem¹, Muhned S Alhumaid¹, Mohammed A Aljatham¹ and Khalid I Zawbae²

¹Department of Adult Hematology Oncology, King Saud Medical City, AlShemisy Area, P.O. Box 366254, Riyadh 11393, Saudi Arabia

²Central Blood Bank, Riyadh Regional Laboratory, Saudi Arabia/Laboratory Department, Directorate of Riyadh Health Affairs, Saudi Arabia

***Corresponding author**

Adel A Aljatham, Department of Adult Hematology Oncology, King Saud Medical City, AlShemisy Area, P.O. Box 366254, Riyadh, Saudi Arabia.

Received: February 06, 2024; **Accepted:** February 28, 2024; **Published:** March 04, 2024

ABSTRACT

Background and Aim: Convalescent plasma (CP) was early and successfully used in management of COVID-19 infection. This report aimed to document our experience with use of CP in two critically-ill COVID-19 patients.

Introduction

The overwhelming challenge caused by COVID-19 pandemic triggered an unprecedented global effort to identify and develop effective medications and vaccines against the disease with different pathological targets, mechanisms, adverse effects and clinical outcomes [1]. Generally, these therapeutics include antiviral and immunomodulatory agents [2]. Among the immunomodulatory agents, passive antibody therapies including neutralizing monoclonal antibodies (mAbs), hyperimmunoglobulin and convalescent plasma (CP) have been early and successfully used [3]. In comparison with monoclonal antibodies, immune plasma from individuals immunized by both a natural SARS-CoV-2 infection and SARS-CoV-2 vaccination retained neutralizing activity against new variants [4].

In this report, we document our experience with use of CP in two critically-ill COVID-19 patients in the early months of the pandemic. The legal guardians of the included patients provided consent to anonymously publish this report.

Case Scenarios

The first patient a 65-year-old male with history of hypertension. He presented to ER department in June, 2020 with 11-day history of fever, dry cough and difficulty of breathing. His peripheral oxygen saturation was 92.0% while receiving 15 L/min. of oxygen via facemask. The patient was prompted to full laboratory assessment and radiological imaging. Laboratory findings are shown in figure.1 Sequential Organ Failure Assessment (SOFA) Score was calculated to be 5 and chest radiograph revealed

70.0% of lung involvement with infiltrates. The patient was admitted to the ICU where he remained spontaneously breathing for 4 days. On deterioration of partial pressure of oxygen / fraction of inspired oxygen (P/F) ratio to 80, he was switched to mechanical ventilation (MV) and maintained on full sedation and vasopressor support. During ICU stay, the patient received anti-viral medications, steroids, tocilizumab and multiple courses of antibiotics according to culture and sensitivity (ceftriaxone initially, followed by azithromycin, then linezolid and imipenem). In addition, he received two sessions of CP (10-15 ml/kg infusion); the first at day 2 after initiation of MV and the second at day 4. CP administration resulted in marked improvement of chest radiographs to 50.0% and 40.0% of lung tissue involvement after the first and second sessions respectively. Also, P/F ratio improved to 500 at day 7 and tested negative for COVID-19 at day 13 of CP initiation. Unfortunately, however, the patient finally died after 45 days of ICU admission due to perforated acalculous cholecystitis, septic shock (main isolated organisms: acinetobacter baumani and staphylococcus capitis) and multi-organ failure.

The second patient is 68-year-old male with history of hypertension, diabetes, coronary heart disease, multiple disc herniations mainly L5-S1 and transient ischemic attacks. Upon presentation to ER in July, 2020, he had complained of fever, dry cough, and difficulty of breathing for 3 days. He had a peripheral oxygen saturation of 91% while receiving 10 L/min. of oxygen via facemask. Laboratory and radiological assessment identified a SOFA score of 4 and bilateral infiltration involving 40% of lungs fields. More laboratory details are illustrated in Figure 1.

Citation: Adel A Aljatham, Waleed T Hashim, Mohamad A Almashiakhi, Abdulrahman M Alharthy, Faisal A Alaklobi, et al. Convalescent Plasma for Critically-ill COVID-19 Patients. *J Infect Dis Treat.* 2024. 2(1): 1-3. DOI: doi.org/10.61440/JIDT.2024.v2.09




Figure 1: Laboratory findings in the studied cases

The patient was admitted to ICU where he received anti-viral therapy, steroids, tocilizumab and empirical antibiotics (started with azithromycin and followed by complete courses of cefepime, vancomycin, and meropenim) due to lack positive cultures from any source. Three days after admission, radiological lung involvement extended to involve 80.0% of lung tissue. On the same day CP administration was initiated and the patient received two sessions. Radiological involvement was reduced to 50.0% and 40.0% of lung tissue at days 14 and 30 after CP use and COVID-19 test turned negative after 15 days of ICU admission. In spite of this improvement, the patient ultimately died after 93 days of ICU admission probably due to thromboembolic events.

Discussion

The present case report illustrates the clinical scenarios of two critically-ill COVID-19 patients who received CP during their ICU stay. While CP administration resulted in marked improvement of radiological findings and/or pulmonary functions, both patients finally died. The unfavorable outcome in our patients is probably attributed to the late use of CP. At this time, the patient usually has developed his own immune response which -if exaggerated- can result in cytokine storm and its consequences. Unfortunately, at the early months of the pandemic, no standardized protocols were available for CP administration.

This suggestion is supported by the conclusions of a recent meta-analysis of 58 randomized controlled trials. It was found that efficacy of CP is better when used in early disease stages [5].

In fact, the value of CP in management of COVID-19 patients is a controversial issue. One meta-analysis dedicated for studies involving outpatient COVID-19 patients revealed that patients who received CP, experienced lower rate of hospitalization with no benefit on survival or clinical outcome [6]. In contrast, another meta-analysis including the same subset of patients found that CP use was able to reduce all- cause mortality particularly when used within 5 days of symptom onset [7].

In hospitalized patients, use of CP resulted in reduction of mortality rate especially when preparations with high antibody levels were used or when CP was used early after hospitalization [8]. However, one case series acknowledged the efficacy and safety of CP even in late-state and severe cases of COVID-19 infection with significant improvement of clinical and laboratory findings and final discharge of 75.0% of patients [9].

In contrast, other studies concluded that CP use has no effect on mortality [10,11] principally in patients with moderate-to-severe illness [12]. This controversy may be explained by the variable clinical characteristics of the studied patients and the variable preparations and protocols of CP administration in different centers.

This explanation is supported by the conclusions of Casadevall et al. who identified three conditions for successful use of CP in COVID-19 patients: 1) Use of specific antibody, 2) early use and 3) sufficient amount of antibodies [13].

Main Findings

Patients presented with fever, dry cough and difficulty of breathing with reduced oxygen saturation, massive radiological lung involvement and deteriorated Sequential Organ Failure Assessment (SOFA) Score. Use of two sessions of CP resulted in marked improvement of radiological and/or pulmonary findings. Both patients died of septic shock or thromboembolic events.

Conclusions

Use of CP may be associated with radiological and clinical improvement in critically-ill patients. However, it's not related to better survival if used in late stages of the disease.

Declarations

This study was approved by the ethical committee of King Saud Medical City

References

1. Aboul-Fotouh S, Mahmoud AN, Elnahas EM, Habib MZ, Abdelraouf SM. What are the current anti- COVID-19 drugs? From traditional to smart molecular mechanisms. *Virology*. 2023. 20: 241.
2. Andrews HS, Herman JD, Gandhi RT. Treatments for COVID-19. *Annu Rev Med*. 2023. 29: 145-157.
3. Yang X. Passive antibody therapy in emerging infectious diseases. *Front Med*. 2023. 17: 1117-1134.
4. Schrezenmeier H, Hoffmann S, Hofmann H, Appl T, Jahrsdörfer B, Seifried E, Körper S. Immune Plasma for the Treatment of COVID-19: Lessons Learned so far. *Hamostaseologie*. 2023. 43: 67-74.
5. Stadler E, Chai KL, Schlub TE, Cromer D, Khan SR, et al. Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis. *Lancet Microbe*. 2023. 4: 883-892.
6. Filippatos C, Ntanasios-Stathopoulos I, Sekeri K, Ntanasios-Stathopoulos A, Gavriatopoulou M, et al. Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials. *Viruses*. 2023. 15: 765.
7. Levine AC, Fukuta Y, Huaman MA, Ou J, Meisenberg BR, et al. Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials. *Clin Infect Dis*. 2023. 76: 2077-2086.
8. Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, et al. Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. *Mayo Clin Proc Innov Qual Outcomes*. 2023. 7: 499-513.
9. Kumar NR, Karanam VC, Kumar S, Kumar SD. Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection. *South Med J*. 2023. 116: 427-433.
10. Mihalek N, Radovanović D, Barak O, Čolović P, Huber M, et al. Convalescent plasma and all- cause mortality of COVID-19 patients: systematic review and meta-analysis. *Sci Rep*. 2023. 13: 12904.
11. Hakim SM, Chikhouni GMA, Ammar MA, Amer AM. Effect of convalescent plasma transfusion on outcomes of coronavirus disease 2019: a meta-analysis with trial sequential analysis. *J Anesth*. 2023. 37: 451-464.
12. Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, et al. Convalescent plasma for people with COVID-19: a living systematic review. *Cochrane Database Syst Rev*. 2023. 5: CD013600.
13. Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, et al. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. *Expert Rev Respir Med*. 2023. 17: 381-395.